Revance Therapeutics Inc expected to post a loss of 95 cents a share - Earnings Preview

Revance Therapeutics

25/02/2023 01:11

* Revance Therapeutics Inc  RVNC.OQ   RVNC.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
28. 
    * The Nashville Tennessee-based  company is expected to
report  a
79.4% increase in revenue to $46.546 million from $25.95 million
a year ago, according to the mean estimate from 10 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Revance
Therapeutics Inc
is for a loss of 95 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Revance
Therapeutics Inc is $34.5​, above​ its last closing price
of $34.12. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.91       -0.89      -1.17     Missed  -30.8
 Jun. 30 2022  -0.89       -0.86      -0.88     Missed  -2.3
 Mar. 31 2022  -0.93       -0.83      -0.94     Missed  -12.6​
 Dec. 31 2021  -0.95       -1.00      -0.93     Beat    6.6
 ​​Sep.        -1.15       -1.15      -1.10     Beat    4.5
 30 2021                                                
 Jun. 30 2021  -1.09       -1.05      -1.07     Missed  -1.6​
 Mar. 31 2021  -1.14       -1.09      -1.08     Beat    0.6
 Dec. 31 2020  -1.29       -1.24      -1.24     Met     -0.2
 This summary was machine generated February 25 at 01:11 GMT. 
All figures in US dollars  unless otherwise stated